Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.

Khosravi MA, Abbasalipour M, Concordet JP, Berg JV, Zeinali S, Arashkia A, Azadmanesh K, Buch T, Karimipoor M
Eur J Pharmacol. 2019 Jul 5;854:398-405. doi: 10.1016/j.ejphar.2019.04.042. Epub 2019 Apr 27. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.